Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease
· sanofi winthrop industrie
AI Briefing
- Sanofi's Rezurock approved for chronic graft-vs-host disease in EU
- Rezurock is the first treatment to target a specific pathway in GvHD
- Approval expands treatment options for patients with this rare and often life-threatening condition
Advertisement